Evidence map›Paper›PMID 42245701›Full record

ArticleFrontiers in oncology2026

Genomic landscape of immune checkpoint inhibitor-induced aplastic anemia: a case report.

Nobuyuki Takahashi, Kenichi Harano, Chikako Funasaka, Hiromichi Nakajima, Chihiro Kondoh, Nobuaki Matsubara, Ako Hosono, Yoichi Naito, Michiko Nagamine, Hiroshi Tanabe and 6 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Nobuyuki TakahashiDepartment of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Kenichi HaranoDepartment of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Chikako FunasakaDepartment of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Hiromichi NakajimaDepartment of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Chihiro KondohDepartment of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Nobuaki MatsubaraDepartment of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Ako HosonoDepartment of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Yoichi NaitoDepartment of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Michiko NagamineDepartment of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.
Hiroshi TanabeDepartment of Gynecology, National Cancer Center Hospital East, Kashiwa, Japan.
Takao FujisawaTranslational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.
Yoshiaki NakamuraTranslational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.
Hideaki BandoTranslational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.
Takayuki YoshinoDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Junichiro YudaDepartment of Hematology and Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Toru MukoharaDepartment of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hematological immune-related adverse events caused by immunotherapy are relatively uncommon. Aplastic anemia triggered by immune checkpoint inhibition is rare and its genomic characteristic remains largely unexplored. This case report describes a 42-year-old female with metastatic cervical cancer who experienced aplastic anemia caused by pembrolizumab. Through a nationwide genomic screening study, MONSTAR-SCREEN-2, we examined genomic landscape of biopsied tissue and circulating tumor DNA. The patient harbored human leukocyte antigen-A*0201 haplotype, which is known as a risk allele of idiopathic acquired aplastic anemia. Clonal hematopoiesis (CH) of myeloid cancer candidate gene

Indexed as

aplastic anemiacase reportclonal hematopoiesisimmune checkpoint inhibitorimmune-related adverse events

Identifiers

PMID42245701
PMCPMC13229815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.